Innovation for fully continuous dialysis
The Austin Technology Incubator is pleased to announce Nephrodite, Inc. as a new addition to its client portfolio. Nephrodite is developing an innovative implantable dialysis device to replace standard, intermittent ‘in-center’ hemodialysis for better outcomes for patients with end-stage kidney disease and a significant increase in quality of life.
New innovation for Better Outcomes for Kidney Disease
Over 2 million people worldwide currently receive life-saving dialysis as a bridge to kidney transplant. Over 750,000 patients in the US with end-stage renal disease on dialysis have an average life expectancy of only 5-10 years because of the complications associated with dialysis. Nephrodite’s team of scientists and medical professionals have developed a patented, fully implantable continuous dialysis device, eliminating the need for ‘in-center’ dialysis thereby resulting in a better quality of life while also decreasing the costs associated dialysis care. They have cleared several major design and development hurdles proving their device’s ability to clear waste products from blood and prevent blood clotting through their proprietary design – all moving towards bringing the device to market.
Commercializing “The Holly™”
Nephrodite envisions a world where dialysis doesn’t mean stopping your life. Their team is dedicated to commercializing The Holly™ to be a bridge to transplant for eligible patients and/or a destination therapy for transplant ineligible patients. The device, inspired by a patient named Holly, serves as a more effective renal replacement therapeutic as it minimizes the impact/burden of treatment, facilitates mobility, and reduces disease maintenance and complications. The Holly is a patent protected device in preclinical development that works while “you do life” without the need to spend waking hours hooked up to externalized machines.
Nephrodite : ATI Relationship
“We are committed to improving the quality of life of dialysis patients through the focused commercialization of “The Holly”, said Dr. Nikhil Shah, Nephrodite’s CEO, ” and working with ATI will help us accelerate our efforts to achieve this goal.’ As a member of ATI, Nephrodite will be able to leverage ATI’s strategic relationships across the Austin ecosystem along with ATI’s extensive network of expert mentors and funding sources. “We are excited to welcome the Nephrodite team to the Austin Technology Incubator and look forward to supporting their important mission to innovate and advance new solutions to address the global unmet need for better outcomes for patients with end-stage kidney disease.,” said Lisa McDonald MD, MSTC, Director of Healthcare at the Austin Technology Incubator.
Nephrodite’s mission is to innovate and advance new solutions to address the global unmet need for better outcomes for patients with end-stage kidney disease. We are developing the Holly™, a fully implantable, mechanical, continuous hemodialysis device designed to be a bridge to transplant for eligible patients and/or a destination therapy for transplant ineligible patients. For more information, please visit nephrodite.com.